September 2014 Newsletter

September 24, 2014:

By the Numbers: European Ophthalmic Meetings Draw Thousands to London

The joint EURETINA, ESCRS, EuCornea, and ESONT meetings, plus several related conferences, were held September 11 to 17.

September 24, 2014:

2014 EURETINA Congress: Retinal Pharmaceuticals and Biologics

September 24, 2014:

2014 EURETINA Congress: Retinal Devices

September 24, 2014:

2014 ESCRS Congress: Intraocular Lenses

September 24, 2014:

2014 ESCRS Congress: Diagnostic Equipment

September 24, 2014:

2014 ESCRS Congress: New Glaucoma Treatments

September 24, 2014:

Retinal Procedure Volume Increases in Q2-2014

Total retinal procedure volume rose 4.9 percent over Q2-2013’s tally and 2.5 percent over the total in Q1-2014.

September 24, 2014:

Cochrane Review Finds Lucentis No Safer than IVT Avastin

Researchers reviewed nine clinical trials and found the risk of death or serious adverse events was similar for the anti-VEGFs.

September 24, 2014:

Modest Growth Forecast for the Single-Use Ophthalmic Surgical Products Market

The market is expected to total $3.2 billion by 2019.

September 24, 2014:

Auxilium Sticks with QLT After Offer from Endo

Auxilium said it would not abandon its acquisition deal with Canadian ophthalmic company.

September 24, 2014:

Beaver-Visitec to Acquire Endo Optiks

The deal is expected to increase BVI’s participation in glaucoma and retinal surgery.

September 24, 2014:

Alcon to Purchase WaveTec Vision

WaveTec sells the ORA System, an intraoperative guidance system for cataract surgeons implanting IOLs.

September 24, 2014:

Valeant Acquires Ophthalmic Products from CROMA

Valeant will distribute the ophthalmic brands in Western Europe and seek approvals for marketing them in the US.

September 24, 2014:

Allergan in Talks with Salix as Battle with Valeant Continues

The maker of Restasis appears to be looking for options ahead of a shareholders’ meeting set for December.

September 24, 2014:

September 2014 News Briefs

Social media